TABLE IV.

In Silico Validation of 28-Gene Signature Using Three External Datasets

	MC	MSKCC	EMC
Tissue used for gene expression and clinical outcomes	333 PM (NED + BCR) versus 212 PM (CR)	131 PM versus 19 tissues from MET lesions	39 PM (non-CR) versus 9 PM (CR)
	AUC (95%CI)	AUC (95%CI)	AUC (95%CI)
USC 28 gene model + clinical variables	0.75 (0.72–0.77)	0.90 (0.86–0.94)	0.82 (0.74–0.91)
Clinical variables only*	0.72 (0.70–0.74)	0.86 (0.82–0.91)	0.76 (0.67–0.85)

PM, primary tumors; NED, no evidence of disease (no recurrence patients); CR, clinical recurrence; MET, metastasis tissue; MC, Mayo Clinic; MSKCC, Memorial Sloan-Kettering Cancer Center; EMC, Erasmus Medical Center; AUC, area under the curve; CI, confidence interval.

^*Clinical variables in model: MC—Gleason score only; MSKCC—age at diagnosis, race/ethnicity, neo-adjuvant treatment, and adjuvant treatment for all patients (no missing data); EMC—pathologic stage and Gleason score (no missing data).